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New ternary copper (II) complexes, [Cu(L-orn)(B)(Cl)](Cl2H2O) (1–2) where L-orn is L-ornithine, B is an
N,N-donor heterocyclic base, viz. 2,20-bipyridine (bpy, 1) and 1,10-phenanthroline (phen, 2), were synthe-
sized and characterized by various spectroscopic techniques. Complex 2 is characterized by the X-ray
single crystallographic method. The complex shows a distorted square-pyramidal (4 + 1) CuN3OCl
coordination sphere. Binding interactions of the complexes with calf thymus DNA (CT-DNA) were inves-
tigated by UV–Vis absorption titration, ethidium bromide displacement assay, viscometric titration
experiment and DNA melting studies. Complex 2 shows appreciable chemical nuclease activity in the
presence of 3-mercaptopropionic acid (MPA). The complexes were subjected to in vitro cytotoxicity
studies against carcinomic human alveolar basal epithelial cells (A-549) and human epithelial (HEp-2)
cells. The IC50 values of 1 and 2 are less than that of cisplatin against HEp-2 cell lines. MIC values for 1
against the bacterial strains Streptococcus mutans and Pseudomonas aeruginosa are 0.5 mM.
 2012 Elsevier Ltd. All rights reserved.1. Introduction
Metal complexes constitute a growing ﬁeld in drug design and
have been considered as promising antitumor agents in recent dec-
ades by the virtue of their unique spectroscopic and electrochem-
ical signatures. The interest in the role of metal complexes in
cancer therapy was triggered by the discovery of the potent epithe-
lial ovarian cancer drug cisplatin [1]. Metal complexes with tun-
able coordination environments and versatile physicochemical
properties offer scope for designing and developing highly sensi-
tive diagnostic agents for medicinal applications [2–17]. Metal
complexes with polypyridyl phenanthroline bases have attracted
great attention by virtue of their binding propensity to nucleic
acids under physiological conditions. In addition to the rich coordi-
nation chemistry of the metal ions, they have great potential in
constructing metal complexes with diverse structures and redox
potentials [18–22]. Coordination compounds of the bioessential
element copper have been extensively used in metal mediated
DNA cleavage through the generation of hydrogen abstracting acti-
vated oxygen species (ROS). Sigman et al. investigated the chemical
nuclease activity of a bis-(1,10-phenanthroline) copper (I) com-
plex, which on activation with H2O2 induced oxidative strandll rights reserved.
.
na).scission [2]. The active oxo species attack the deoxyribose sugar
proton of the nucleotide, which is in the vicinity of the copper (I)
bisphen species in the minor groove, oxidatively initiating a series
of free radical chain reactions to induce DNA strand scission
[23,24]. The strong binding afﬁnity of the copper bis phen complex
and the redox behavior of the copper center play an important role
in inducing oxidative DNA cleavage. Chakravarty and co-workers
recently explored amino acid transition metal based chemistry to-
wards cleavage of DNA under physiological conditions by oxidative
as well as photochemical means on charge transfer or d–d band
excitation [25–39]. The copper complex of L-lysine structure is clo-
sely resembles the copper–ornithine structure, which shows efﬁ-
cient chemical nuclease activity [25]. The present work stems
from our interest to explore chemical nuclease activity, cytotoxic-
ity against A-549 and HEp-2 cancer cells and antimicrobial activi-
ties of L-ornithine copper (II) complexes.
Compounds with a-amino acids containing a terminal amine
moiety easily penetrate through cell walls due to their ionic char-
acter. L-Ornithine is a non-protein, basic amino acid and it is most
potent for stimulating, production and release of growth hor-
mones, in maintaining arterial ﬂexibility and defeating hyperten-
sion [40–42]. Ornithine decarboxylase activity is higher in
rapidly growing tumors than in non-malignant tumors [43–45].
This activity may be reduced by chelating the carboxylate group
of ornithine. Due to these activities of L-ornithine, we were inter-
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copper complexes.
Herein, we report the two new ternary copper (II) complexes
[Cu(L-orn)(B)(Cl)](Cl2H2O) (1–2), where L-orn is L-ornithine, B is
N,N-donor heterocyclic base, viz. 2,20-bipyridine (bpy, 1) and
1,10-phenanthroline (phen, 2), which were synthesized and char-
acterized by various spectroscopic techniques. Complex 2 is char-
acterized by single X-ray crystallographic method. Studies have
been made to explore the role of a DNA binder and amino acid with
a terminal amine group along with the mechanistic pathways in-
volved in the chemical nuclease activity.Scheme 1. Schematic representation of complexes 1 and 2.2. Experimental
2.1. Materials and methods
The reagents and chemicals were purchased from commercial
sources and used as received without further puriﬁcation. The sol-
vents used were puriﬁed by standard procedures [46]. Supercoiled
(SC) pUC19 DNA (cesium chloride puriﬁed) was purchased from
Bangalore Genie (India). CT-DNA, agarose (molecular biology
grade), distamycin-A, catalase, superoxide dismutase (SOD) and
ethidium bromide (EB) were from Sigma (USA). Tris(hydroxy-
methyl)aminomethane–HCl (Tris–HCl) buffer was prepared using
deionized and sonicated triple distilled water. The elemental anal-
ysis was done using a Thermo Finnigan FLASH EA 1112 CHNS ana-
lyzer. The infrared and electronic spectra were recorded on Perkin
Elmer Lambda 35 and Perkin Elmer spectrum one 55 spectropho-
tometers respectively at 25 C. Magnetic susceptibility data for
polycrystalline samples of the complexes were obtained using a
Model 300 Lewis-coil-force magnetometer of George Associates
Inc. (Berkeley, USA) make and Hg[Co(NCS)4] was used as a stan-
dard. Experimental susceptibility data were corrected for diamag-
netic contributions [47]. Molar conductivity measurements were
carried out using a Control Dynamics (India) conductivity meter.
Cyclic voltammetric measurements were made at 25 C on a
EG&G PAR 253 Versastat potentiostat/galvanostat using a three
electrode conﬁguration consisting of a glassy carbon working, a
platinum wire auxiliary and a saturated calomel reference (SCE)
electrode.2.2. Synthesis
2.2.1. Preparation of [Cu(L-orn)(B)(Cl)](Cl) (1–2) (L-orn = L-ornithine
and B = bpy, 1; phen, 2)
An aqueous solution of CuCl23H2O (0.48 g, 2 mM) was reacted
with L-ornithine which was pre-treated with NaOH (0.08 g,
2.0 mM) in water (10 mL) and stirred for 2 h at room temperature.
A 20 mL methanolic solution of the heterocyclic base [bpy (0.28 g),
phen (0.35 g)] was added dropwise using a syringe at room tem-
perature. The solid that formed was ﬁltered and the ﬁltrate, on
slow concentration, yielded a blue crystalline solid of the com-
plexes (Scheme 1).
Anal. Calc. for C15H24CuN4O4Cl2 (1): C, 39.23; H, 5.23; N, 12.20.
Found: C, 39.64; H, 5.24; N, 12.73%. FT-IR, cm1 (KBr disc): 3107br,
3051w, 1608s, 1560m, 1494m, 1471s, 1442vs, 1315s [br, broad; vs,
very strong; s, strong; m, medium; w, weak]. UV–Vis in water
[kmax, nm (e, M1 cm1)]: 312 (7590), 588 (75). Magnetic moment
at 298 K [leff/BM]: 1.56. KM (X1 cm2 M1) in water at 25 C: 143.
ESI-MS in methanol m/z: 417.41 [MCl]+.
Anal. Calc. for C17H24CuN4O4Cl2 (2): C, 42.36; H, 4.99; N, 11.63.
Found: C, 42.32; H, 4.94; N, 11.61%. FT-IR, cm1 (KBr disc): 3252br,
3446br, 3247m, 3128w, 1172w, 1622vs, 1514m, 1421m, 848m,
721m. Magnetic moment at 298 K [leff/BM]: 1.79. UV–Vis in water
[kmax, nm (e, M1 cm1)]: 789 (13), 626 (72), 610 (65), 376 (903),232 (1356), 208 (1168). KM (X1 cm2 M1) in water at 25 C:
137. ESI-MS in methanol m/z: 443.44 [MCl]+.
2.3. X-ray crystallographic procedures
Single crystals of 2 were grown by slow evaporation of water/
methanol mixture. A block shaped single crystal was mounted on
a glass ﬁber with epoxy cement. The X-ray diffraction data were
measured in frames with increasing x (width of 0.3 per frame)
and with a scan speed of 15 s/frame on a Bruker SMART APEX
CCD diffractometer, equipped with a ﬁne focus 1.75 kW sealed
tube X-ray source. Empirical absorption corrections were carried
out using the multi-scan program [48]. The structure was solved
by the heavy atom method and reﬁned by full matrix least-squares
using the SHELX system of programs [49]. All non-hydrogen atoms
were reﬁned anisotropically and the hydrogen atoms were reﬁned
isotropically. The hydrogen atoms attached to the hetero atoms
were in their calculated positions and reﬁned according to the rid-
ing model. The perspective view of the complex was obtained by
ORTEP [50].
2.4. DNA binding and cleavage experiments
DNA binding experiments were performed in Tris–HCl/NaCl
buffer (5 mM Tris–HCl, 5 mM NaCl, pH 7.2) using an aqueous solu-
tion of the complexes. CT-DNA (ca. 250 lM NP) in Tris–HCl buffer
medium gave a ratio of the UV absorbances at 260 and 280 nm of
ca.1.9:1, indicating the purity of DNA which is apparently free from
protein [51]. The concentration of DNA was calculated from its
absorption intensity at 260 nm with the known molar absorption
coefﬁcient value of 6600 M1 cm1 [52]. UV–Vis absorption titra-
tion experiments were performed by varying the concentration
of CT-DNA keeping the metal complex concentration constant
(50 lM) with due correction for the absorbance of CT-DNA itself.
Samples were allowed to get equilibrated to bind sufﬁciently to
CT-DNA before recording each spectrum. The intrinsic equilibrium
binding constant (Kb) and the binding site size (s) of the complex
were determined from a non-linear ﬁtting of the plot of Deaf/Debf
versus [DNA] using the McGhee–von Hippel (MvH) method. The
expression of Bard and coworkers: Deaf/Debf = (b  (b2  2Kb2Ct[-
DNA]/s)½)/2Kb, b = 1 + KbCt + Kb[DNA]/2s was used to evaluate Kb
and s, where Kb is the microscopic equilibrium binding constant
for each site, Ct is the total concentration of the metal complex, s
is the site size of the metal complex interacting with the DNA,
[DNA] is the concentration of DNA in nucleotides, ef, ea and eb are
respectively the molar extinction coefﬁcients of the free complex
in solution, complex bound to DNA at a deﬁnite concentration
and the complex in the completely bound form with CT-DNA
Fig. 1. The electronic spectra of complexes 1 (. . .) and 2 (—) in water, inset shows
the d–d band of 2.
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gin Lab software, version 6.1.
The ﬂuorescent spectral measurements were done using an
ethidium bromide (EB) bound CT-DNA solution (260 lM) in
5 mM Tris–HCl buffer (pH 7.2) at 25 C. EB itself did not show
any ﬂuorescence in Tris–HCl buffer medium as its ﬂuorescence
was quenched due to collision of EB with the excess solvent mole-
cules [55,56]. EB showed enhanced ﬂuorescence emission due to
its intercalation to CT-DNA which make EB inaccessible to the sol-
vent molecule. The ﬂuorescent intensity of EB bound CT-DNA at
600 nm with increasing concentration of the complex was re-
corded. The addition of metal complex to CT-DNA could result in
the competitive displacement of EB and hence a decrease in the
emission intensity. The apparent binding constants (Kapp) for the
complexes were determined by using the equation: Kapp[com-
plex] = KEB[EB] [57].
DNA-melting experiments were carried out by monitoring the
absorbance of CT-DNA (260 nm) with increasing temperature in
the absence and presence of the complexes in a molar ratio of
10:1 of the CT-DNA and the complex in phosphate buffer medium
(pH 6.8) with a ramp rate of 0.5 C min1 using a Cary Bio UV–Vis
spectrophotometer.
Viscometric titration experiments were performed using a
Schott Gerate AVS310 automated viscometer that was thermo-
stated at 37 (±0.1) C in a constant temperature bath. The concen-
tration of CT-DNA was 170 lM. The ﬂow time was measured with
an automated timer. The data were presented by plotting the rela-
tive speciﬁc viscosity of DNA, (g/g0)1/3 versus R, where g is the vis-
cosity of DNA in the presence of the complex and g0 is the viscosity
of DNA alone in 5 mM Tris–HCl buffer medium, R = [complex]/
[DNA]. The viscosity values were calculated from the observed ﬂow
time of CT-DNA containing solutions (t), duly corrected for that of
the buffer alone (t0), g = (t  t0)/t0.
The oxidative cleavage of SC pUC19 DNA by the ternary copper
(II) complexes was studied by agarose gel electrophoresis. MPA
(5 mM) was used as the reducing agent for the chemical nuclease
activity. Reactions were carried out in the dark at 25 C using SC
DNA (1 lL, 0.2 lg 30 lM) in 50 mM Tris–HCl buffer (pH 7.2) con-
taining 50 mM NaCl and the complexes (2 lL) with varied concen-
trations. The concentration of the complexes in DMF or the
additives in buffer corresponded to the quantity after the dilution
of the complex stock to the 20 lL ﬁnal volume using Tris–HCl buf-
fer. The SC pUC19 DNA samples were pre-incubated for 1 h at
37 C, followed by its addition to the loading buffer containing
0.25% bromophenol blue, 0.25% xylene cyanol and 30% glycerol
(2 lL) and the solution was ﬁnally loaded on 0.8% agarose gel con-
taining 1.0 lg mL1 ethidium bromide (EB). The electrophoresis
experiment was carried out in a dark room for 2 h at 45 V in TAE
(Tris–acetate–EDTA) buffer. The bands were visualized by UV light
and photographed. The extent of cleavage of SC-DNA was deter-
mined by measuring the intensities of the bands using a UVITECH
Gel Documentation System. Due corrections were made for the low
level of nicked circular (NC) form present in the original SC-DNA
sample and for the low afﬁnity of EB binding to SC compared to
NC and linear forms of DNA [58]. Different additives were added
to the SC DNA for mechanistic investigations in the presence of
the copper (II) complexes.
2.5. Cytotoxicity assay
Cell cultures were obtained from Christian Medical College, Vel-
lore. A-549 cells and HEp-2 were grown in Dulbecco’s Modiﬁed Ea-
gle’s Medium (DMEM) supplemented with 2 mM L-glutamine, 10%
fetal bovine serum, penicillin (100 lg/mL), streptomycin (100 lg/
mL) and amphoterecin B (5 lg/mL). The cells were maintained at
37 C in a humidiﬁed atmosphere with 5% CO2 and subculturedonce a week. Sulforhodamine B (SRB) assay was conducted as per
the reported procedures [59]. A-549 (human alveolar basal epithe-
lial cells) cells are squamous in nature, responsible for the diffusion
of substances such as water and electrolytes across the alveoli of
lungs. HEp-2 cells resist temperature, nutritional and environmen-
tal changes without a loss of viability. They support the growth of
arbo viruses and measles virus.
2.6. Antimicrobial activity
The antibacterial activity was tested against clinical isolates like
Bacillus subtilis, Micrococcus luteus, Staphylococcus aureus, Strepto-
coccus mutans, Escherichia coli, Pseudomonas aeruginosa and Proteus
vulgaris. The test organisms were maintained on nutrient agar
slants. In-vitro antibacterial activity was determined by the agar
well-diffusion method as described by Mukherjee et al. [60]. The
overnight bacterial culture was centrifuged at 8000 rpm for
10 min. The bacterial cells were suspended in saline to make a sus-
pension of 105 CFU/mL and used for the assay. Plating was carried
out by transferring the bacterial suspension to a sterile Petri plate,
mixed with molten nutrient agar medium, and allowing the mix-
ture to solidify. About 75 lL of the sample (2 mg/mL) was placed
in the wells. Plates were incubated at 37 C and activity was deter-
mined by measuring the diameter of the inhibition zones. The as-
say was carried out in triplicate. The MIC was determined
according to the method described by Jones et al. [61]. Different
concentrations of the compounds and 100 lL of the bacterial sus-
pension (105 CFU/mL) were placed aseptically in 10 mL of nutrient
broth separately and incubated for 24 h at 37 C. Growth was ob-
served at regular intervals followed by pour plating as described
above. The lowest concentration of the test sample showing no vis-
ible growth was recorded as the MIC. Triplicate sets of tubes were
maintained for each concentration of test sample.
3. Results and discussion
3.1. Synthesis and general properties
The complexes are one electron paramagnetic at room temper-
ature, corresponding to d9 electronic conﬁguration for the copper
(II) center. The complexes display a copper (II) centered d–d band
at 600 nm in addition to the ligand centered bands in the UV
region of the electromagnetic spectra (Fig. 1). The electronic
spectra of the complexes are in good agreement with the previ-
ously reported square pyramidal geometry of the complexes
[36,37]. The complexes show a metal centered quasi-reversible
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0.5 V versus SCE in DMF 0.1 M TBAP.Fig. 2. ORTEP view of the complex [Cu(L-orn)(phen)(Cl)]Cl2H2O (2) showing thermal
ellipsoids at the 50% probability level. The atom labeling scheme is shown for the
metal ion and the heteroatoms. Hydrogen atoms and water molecules of crystal-
lization are omitted for clarity.
Table 2
Selected bond distances (Å) and bond angels () for the complex [Cu(L-
orn)(phen)(Cl)]Cl2H2O (2).
Cu(1)–N(1) 2.000(2) N(1)–Cu(1)–Cl(1) 99.39(8)
Cu(1)–N(2) 2.052(2) N(3)–Cu(1)–Cl(1) 96.34(9)
Cu(1)–N(3) 2.015(3) N(2)–Cu(1)–Cl(1) 98.46(10)
Cu(1)–O(1) 1.955(2) C(10)–N(2)–Cu(1) 130.2(2)
Cu(1)–Cl(1) 2.542(11) C(1)–N(1)–Cu(1) 127.6(2)
O(1)–Cu(1)–N(1) 88.75(9) C(12)–N(1)–Cu(1) 113.8(2)
O(1)–Cu(1)–N(3) 82.31(9) O(1)–Cu(1)–Cl(1) 103.92(9)
N(1)–Cu(1)–N(3) 163.40(12) N(1)–Cu(1)–Cl(1) 99.39(8)
O(1)–Cu(1)–N(2) 156.76(12) O(1)–Cu(1)–Cl(1) 103.92(9)
N(1)–Cu(1)–N(2) 81.44(9) N(1)–Cu(1)–Cl(1) 99.39(8)
N(3)–Cu(1)–N(2) 101.52(10) N(2)–Cu(1)–Cl(1) 98.46(10)
O(1)–Cu(1)–Cl(1) 103.92(9) N(3)–Cu(1)–Cl(1) 96.34(9)3.2. Crystal structure
Complex 2 was structurally characterized by the single-crystal
X-ray diffraction technique. It crystallized in the monoclinic P21
space group with two independent molecules in the crystallo-
graphic asymmetric unit and a goodness-of-ﬁt 1.09. The unit cell
packing contains two complex ions, [Cu(L-orn)(phen)(Cl)]+, four
uncoordinated water molecules and two chloride ions. Selected
crystallographic data are summarized in Table 1. The ORTEP view
of 2 is shown in Fig. 2. Selected bond distances and angles are given
in Table 2. The copper (II) complex displays a distorted (4 + 1)
square-pyramidal geometry, in which Cu2+ coordinates with two
nitrogen atoms of 1,10-phenanthroline, one nitrogen atom of an
amino group, one carboxylate oxygen atom of L-ornithine in the
equatorial positions and Cl at the elongated apical position. The
conﬁguration at the chiral a-carbon is S in the complex. The aver-
age trigonal distortion parameter (s) value in the structure is 0.110.
The average Cu–N1(phen), Cu–N2(phen), Cu–O(L-orn), Cu–N(L-orn)
and Cu–Cl bond distances are 2.000(2), 2.052(2), 1.955(3), 2.015(2)
and 2.542(11) Å, respectively. The alkyl chain of the cationic amino
group –(CH2)3NH3+ remains as a pendant moiety. The X–Cu–Z an-
gles are in the range 163.4(12)–156.76(12), where X and Z are any
two atoms which lie trans to each other, and the X–Cu–Y angles
range from 81.44(9) to 101.52(10), where X and Y are any two
atoms which lie cis to each other. The square pyramidal geometry
around the central metal atom is severely distorted. The structure
show extensive intermolecular non-covalent interactions. The
water molecule is involved in hydrogen bonding interactions with
the terminal cationic amine (NH3+) of L-ornithine. The terminal
amine forms two H bonds with two lattice water molecules
N(4)–Ow(1) and N(4)–Ow(2) (distances: 2.931 and 2.879 Å). The
free oxygen atom of the carboxylate group of L-ornithine forms
two H bonds, one with lattice water (O2–Ow2) and other with
the lattice water of another asymmetric unit (O2–Ow(1)) with dis-
tances of 2.927 and 2.781 Å respectively. The Cl axial ligand is H
bonded with the lattice water of another asymmetric unit with a
distance of 3.238 Å. The lattice Cl is H bonded with latice water,
Ow(1)–Cl(2), with a distance of 3.126 Å.Table 1
Selected crystallographic data for 22H2O.
Empirical formula C17H24Cl2CuN4O4
Formula weight 482.84
Crystal system monoclinic
Space group P21
Unit cell dimensions
a (Å) 10.2680(4)
b (Å) 6.7945(3)
c (Å) 14.9682(6)
b () 108.773(2)
V (Å3) 988.72(7)
Z 2
T (K) 293(2)
qcalc (g cm3) 1.622
k (Å) (Mo Ka) 0.71073
l (cm1) 1.407
Data/restraints/parameters 2947/1/253
F(000) 498
Goodness-of-ﬁt 1.09
R (Fo),a I > 2r(I)/wR(Fo)b 0.0275/0.0774
R (all data)/wR (all data) 0.0295/0.0789
Largest difference in peak and hole (e Å3) 0.440, 0.273
a R = R||Fo|  |Fc||/R|Fo|.
b wR = {R[w(Fo2  Fc2)2]/R[w(Fo)2]}½; w = [r2(Fo)2 + (AP)2 + BP]1, where
P = (Fo2 + 2Fc2)/3, A = 0.0480, B = 0.0341 for 22H2O.3.3. DNA binding studies
The binding interactions of the complexes with CT-DNA have
been investigated by absorption, emission spectroscopic, viscomet-
ric titration and DNA melting techniques. UV–Vis absorption spec-
tral measurements were carried out to evaluate the equilibrium
binding constant (Kb) and binding site size (s) of the complexes
to CT-DNA by monitoring the change in the absorption intensity
of the spectral band at 300 nm for both complexes. Complex 2
showed a minor bathochromic shift of 3 nmwith signiﬁcant hyp-
ochromism of 10–20%, suggesting mainly a groove binding propen-
sity to the ds DNA (Fig. 3). The binding constant (Kb) and binding
site size (s) values for 2 are 2.7 (±0.6)  104 M1 and 0.12 respec-
tively. It shows an efﬁcient DNA groove binding propensity. The
bpy complex 1, which lacks a planar aromatic system, displays a
poor binding afﬁnity to the double stranded CT-DNA. The binding
site size (s), which is a measure of the number of DNA base pairs
associated with the complex, suggests primarily a DNA groove-
binding nature of the complex in preference to intercalation. The
low value of s (61) suggests surface aggregation of hydrophobic
molecules on DNA due to p-stacking or an electrostatic interaction
[62].
The emission spectral method is used to study the relative bind-
ing of the complexes to CT-DNA. The emission intensity of ethi-
dium bromide (EB) is used as a spectral probe. EB shows reduced
emission intensity in buffer solution because of solvent quenching
and an enhancement of the emission intensity when intercalative-
ly bound to DNA. The binding of the complexes to DNA decreases
the emission intensity of EB. The relative binding propensity of
the complexes to DNA is measured from the extent of reduction
in the emission intensity (Fig. 4). The apparent binding constant
(Kapp) values for 1 and 2 are 0.68  105 and 1.6  105 M1
respectively.
Fig. 3. Absorption spectral traces showing the decrease of absorption intensity on
gradual addition of CT-DNA (250 lM, in aliquots to the solution of 2 (40 lM) in
5 mM Tris–HCl buffer (pH 7.2) at 25 C. Inset shows the plot of Deaf/Debf vs. [DNA].
Fig. 4. Emission spectral changes on addition of 2 to CT-DNA bound to ethidium
bromide (shown by arrow). Inset: Effect of addition of complex 1 (N), 2 (j) to the
emission intensity of CT-DNA-bound ethidium bromide in 5 mM Tris–HCl/5 mM
NaCl buffer (pH 7.2) at 25 C.
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the propensity of DNA binding by the complexes. Viscosity mea-
surements are very sensitive to length change and are a critical test
of the binding model in solution. A signiﬁcant increase in the vis-
cosity of DNA on addition of any external species can result only
when there is intercalation, as the intercalation leads to the sepa-
ration among the DNA bases and hence an increase in the effective
size of DNA which could be the reason for the increase in viscosity
[63]. However, in the present case the decrease in the DNA solutionFig. 5. (a) Effect of increasing amounts of the complexes [Cu(L-orn)(bpy)(Cl)] (1) (j) and
5 mM Tris–HCl buffer (pH, 7.2) [DNA] = 150 lM and R = [complex]/[DNA]. (b) DNA meltin
phosphate buffer (pH 6.8).viscosity is attributed to the binding between the complex ion and
DNA through charge afﬁnity or groove binding, which leads to a
destruction of the DNA structure. Partial/non-classical intercala-
tion of a drug molecule could bend the DNA helix, that reduces
its effective length and hence its viscosity. The binding of the com-
plex with DNA could be by a surface or groove binding mode. A
plot of (g/g0)1/3 versus [complex]/[DNA] gives a measure of the vis-
cosity changes (Fig. 5a). A marginal decrease of the relative viscos-
ity was observed on addition of complex to DNA, suggesting
mainly the groove binding nature of the complexes [64]. The de-
crease in viscosity may be due to the perturbation of the structural
network of DNA caused by binding of the complex molecule.
The nature of the binding of the complexes to CT-DNA was fur-
ther investigated by DNA melting experiment. DNA melting is ob-
served when ds DNA molecules are heated and separated into two
single strands; it occurs due to a disruption of the intermolecular
forces, such as p stacking and hydrogen bonding interactions, be-
tween DNA base pairs. The DNA melting experiment revealed that
the melting temperature of CT-DNA was 69.3 ± 0.2 C and
70.5 ± 0.2 C in the absence and presence of 2 respectively. How-
ever, for the individual ligands, there is no considerable change
in the DNA melting temperature. The DNA denaturation experi-
ment showed only a minor shift in the melting temperature (Tm),
giving a DTm value of 1.2 C on addition of 2 to CT-DNA (Fig. 5b).
The low value of DTm suggests primarily a groove-binding prefer-
ence of the complex to DNA.
3.4. Chemical nuclease activity
DNA cleavage activity of the complexes in the presence of MPA
(500 lM) has been investigated using plasmid SC pUC19 DNA
(30 lM, 0.2 lg) in 50 mM Tris–HCl buffer/50 mM NaCl (pH 7.2).
The extent of DNA cleavage was observed by agarose gel electro-
phoresis. A 2 lM concentration of 2 completely cleaves SC-DNA
into its nicked circular (NC) form in the presence of 500 lM MPA
(Fig. 6 and Table 3). Control experiments using SC pUC19 DNA
were carried out to study the mechanistic pathway. MPA
(500 lM) or the complexes individually do not show any apparent
cleavage of SC-DNA under similar reaction conditions (Table 3).
The reaction of SC-DNA with copper (II) salts in the presence of
MPA does not exhibit any cleavage activity. All the control results
suggest that the complexes are responsible for the chemical nucle-
ase activity. The mechanism for the chemical nuclease activity of
the complexes was investigated in the presence of various quench-
ers for reactive oxygen species. Addition of hydroxyl radical scav-
engers, viz. DMSO, KI or catalase, signiﬁcantly inhibits the
cleavage, so the formation of a hydroxyl (OH) radical during the
redox reaction involving the copper (II) center in the presence of
MPA is a possibility. On the contrary, singlet oxygen scavengers
like NaN3 or TEMP (2,2,6,6-tetramethylpiperidine) do not show
any appreciable inhibitory effect on the chemical nuclease activityCu(L-orn)(phen)(Cl)] (2) (d)] on the relative viscosities of CT-DNA at 37.0 (±0.1) C in
g plots for CT-DNA (160 lM NP) in the absence and presence of 2 (20 lM) in 5 mM
Fig. 6. Gel electrophoresis diagram showing the oxidative cleavage of SC pUC19DNA
(0.2 lg) 30 lM, by the complexes (1–2) in the presence of 500 lM MPA in 50 mM
Tris–HCl/NaCl buffer (pH, 7.2). lane-1, DNA control; lane-2, DNA + MPA; lane-3,
DNA + 2 (2 lM); lane-4, DNA + 2 (2 lM) + MPA; lane-5, DNA + 2 (2 lM) + MPA + -
methyl green; lane-6, DNA + 2 (2 lM) + MPA + NaN3; lane-7, DNA + 2
(2 lM) + MPA + SOD; lane-8, DNA + 1 (2 lM); lane-9, DNA + 1 + MPA; lane-10,
DNA + 2 + MPA + dist-A; lane-11, DNA + 2 + MPA + catalase; lane-12, DNA + 2 +
MPA + DMSO; lane-13, DNA + 2 + MPA + TEMP; lane-14, DNA + MPA + ornithine.
Table 3
Selected DNA cleavage data for the complexes 1 and 2.
Sl. No. Reaction conditions % SC % NC
1 DNA control 98 2
2 DNA + MPA 95 5
3 DNA + 2 96 4
4 DNA + 2 + MPA 4 96
5 DNA + 2 + MPA + methyl green 10 90
6 DNA + 2 + MPA + NaN3 9 91
7 DNA + 2 + MPA + SOD 11 89
8 DNA + 1 98 2
9 DNA + 1 + MPA 81 19
10 DNA + 2 + MPA + dist. A 83 17
11 DNA + 2 + MPA + catalase 91 9
12 DNA + 2 + MPA + DMSO 82 18
13 DNA + 2 + MPA + TEMP 22 78
14 DNA + 2 + MPA + ornithine 96 4
[Complex] = 2 lM; [MPA] = 500 lM. DMSO = 6 lL. Catalase = 2 unit. SOD = 2 unit.
[NaN3] = 200 lM. [TEMP] = 200 lM. [dist.-A] = 100 lM.
Table 4
IC50 values for the complexes (1–2) against A-549 and HEp-2 cell lines.
Complex Cell lines
A-549
lg/mL (lM)
HEp-2
lg/mL (lM)
[Cu(om)(bpy)(Cl)]Cl2H2O (1) 9.50 (20.1) 10.0 (22.08)
[Cu(om)(phen)(Cl)]Cl2H2O (2) 1.15 (2.38) 0.60 (1.24)
aCisplatin 0.45 (1.5) 28.2 (94)
aTaxol 4.50 (5.27) –
Each value represents the mean of three trials.
a Positive control.
Fig. 7. Morphological changes after treating 2 with HEp-2 cells after an incubation
period of 1 h. (a) Normal HEp-2 cell (b) targeted HEp-2 cells after 1 h.
Table 5
Minimum inhibitory concentration for the complexes (1–2) and the ligands lg/mL
(mM).
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MPA probably proceeds through the hydroxyl radical pathway. To
determine the groove selectivity of the complexes, control experi-
ments were performed using the minor groove binder distamycin
A and the major groove binder methyl green. The presence of
methyl green does not inhibit the DNA cleavage and the presence
of distamycin A signiﬁcantly inhibits the DNA cleavage, suggesting
the minor groove binding propensity of 2 to the ds DNA.Bacterial strains 1 2 bpy phen
B. subtilis 475 (1.01) – – 450 (2.50)
M. luteus 325 (0.67) 500 (3.2) 500 (3.2) 1000 (5.50)
S. aureus 2000 (4.14) – – 2000 (11.10)
S. mutans 250 (0.51) 1000 (6.4) 1000 (6.4) 1000 (5.50)
E. coli 350 (0.72) – – 500 (2.75)
P. aeruginosa 250 (0.51) – – 1000 (5.50)
P. vulgaris 275 (0.57) – – 1000 (5.50)4. Cytotoxicity assay
4.1. Cytotoxicity of copper (II) complexes of ornithine
A-549 and HEp-2 cells were cultured in the presence of varying
concentrations of the copper (II) complexes of ornithine for 1 h andthe cytotoxicity was analyzed by sulforhodamine B (SRB) assay.
Cisplatin and Taxol were used as a positive control. The IC50 values
for all the compounds were determined and are given in Table 4.
Complex 2 has an IC50 value of 1.15 lg/mL (taxol, 4.5; cisplatin,
0.45 lg/mL) and 0.60 lg/mL (cisplatin, 28.2 lg/mL) against A-549
and HEp-2 cells respectively. All the other appropriate ligands
and the metal salt used in the synthesis were tested and they
had no considerable IC50 values. The morphological changes in
the HEp-2 cell lines after treatment with 2 are shown in Fig. 7.5. Antimicrobial activity
The antimicrobial activities of 1, 2, the ligands and the copper
salt were evaluated against a panel of pathogenic bacterial strains
by the disc diffusion and serial dilution method in aqueous med-
ium. MIC values (lg/mL) for 1, 2, bpy and phen are summarized
in Table 5. The ionic complexes of the transition metal interfere
with the transport of substrates and ions through the cell mem-
brane, resulting in antibacterial activity. The results indicate that
complex 1 exhibits relatively high antibacterial activity against S.
mutans and P. vulgaris compared to its ligands and 2. On chelation,
the polarity of the metal ion will be reduced to a greater extent due
to the overlapping of the ligand orbital and the partial sharing of
the positive charge of the metal ion with the donor groups. Further,
it increases the delocalization of p-electrons over the whole che-
late ring and enhances the lipophilicity of the complexes. This in-
creased lipophilicity enhances the penetration of the complexes
P.R. Chetana et al. / Polyhedron 48 (2012) 43–50 49into lipid membranes, interferes with enzyme activity and may
lead to cell apoptosis. The antifungal activity against Candida albica
for 1, 2 and the ligands was investigated, and considerable activity
was not observed under the assay conditions.6. Conclusion
Two new ternary copper (II) complexes having N,O-donor
L-ornithine and N,N-donor heterocyclic base (B) are prepared and
structurally characterized. The planarity and extended conjugation
of the phenanthroline ligand have a profound effect on the DNA
binding and cleavage activity of the complexes. Complex 2 shows
efﬁcient chemical nuclease activity in the presence of MPA. Path-
ways involving hydroxyl radicals in the DNA cleavage reactions
are proposed from control studies, which show inhibition of the
cleavage in the presence of the hydroxyl radical scavengers DMSO,
catalase and KI. The long aliphatic chain with a terminal positive
pendant of the ornithine complex may marginally enhance the
DNA cleavage activity. The DNA cleavage activity of transition me-
tal complexes with bio-essential constituents like copper and ac-
tive amino acids showing DNA cleavage have the potential for
cellular applications in chemotherapeutic agents. Complex 2 has
promising anticancer activity against HEp-2 cell lines. Complex 1
is an active antibacterial agent against S. mutans and P. aeruginosa.Acknowledgments
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Detailed crystallographic data for the structural analysis, giving
atomic coordinates, thermal parameters and structure reﬁnement
parameters, have been deposited with the Cambridge Crystallo-
graphic Data Centre. CCDC 803869 contains the supplementary
crystallographic data for 2. These data can be obtained free of
charge via http://www.ccdc.cam.ac.uk/conts/retrieving.html, or
from the Cambridge Crystallographic Data Centre, 12 Union Road,
Cambridge CB2 1EZ, UK; fax: (+44) 1223-336-033; or e-mail:
deposit@ccdc.cam.ac.uk.References
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